Plain-English translation of NCT07209241 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new immunotherapy called CART-EGFR-IL13Rα2 cells, which are specially designed immune cells created from a patient's own cells to fight brain cancer. Researchers are comparing different ways of giving this treatment—either as a single dose or repeated doses, and at different times before or after surgery—to see which approach is safest and most effective for people with recurrent glioblastoma.
Glioblastoma is an aggressive brain cancer that often comes back even after radiation therapy, and patients need new treatment options when this happens. This trial is exploring whether this new cell-based treatment could help patients whose tumors have recurred and improve their outcomes.
If you join this trial, you will receive chemotherapy to prepare your body, followed by an infusion of the specially designed cells. Depending on which group you're assigned to, you may receive a single dose or multiple doses of the treatment, either before or after surgery to remove the tumor. You'll have regular follow-up visits to monitor how the treatment is working, check for side effects, and have blood tests and imaging scans.
AI-generated summary from trial data · Sep 5, 2026 · Not medical advice
United States
Phase
Safety & dosing
Sponsor
University of Pennsylvania
Enrollment target
~12 participants
Started
December 2025
Primary completion
November 2042
Age range
18 Years and older
Last updated on clinicaltrials.gov in August 2026.